|
|
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma
Anais Schavgoulidze
,
Valérie Lauwers-Cances
,
Aurore Perrot
,
Titouan Cazaubiel
,
Marie-Lorraine Chretien
,
et al.
Article dans une revue
hal-03801805v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience
Alexis Caulier
,
Murielle Roussel
,
Pierre Morel
,
Naelle Lombion
,
Benoit Branco
,
et al.
Article dans une revue
hal-03578209v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau
,
Michel Attal
,
Cyrille Hulin
,
Bertrand Arnulf
,
Karim Belhadj
,
et al.
Article dans une revue
hal-03605015v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial
Francois Guilhot
,
Françoise Rigal-Huguet
,
Joëlle Guilhot
,
Agnès-Paule Guerci-Bresler
,
Frédéric Maloisel
,
et al.
Article dans une revue
hal-03122967v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|